AVR-RD-02
Biologic
AVR-RD-02 is one of 23 biologic programs targeting Gaucher Disease. It is currently in development.
1
Indications
2
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Gaucher Disease
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Approved
Busulfex
Akero TherapeuticsApproved
Opfolda
Johnson & JohnsonPhase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
ELELYSO
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cerdelga
GGenzyme, a Sanofi Company
Phase 3
Cerezyme
SanofiApproved
CEREZYME
GGenzyme, a Sanofi Company
Phase 3
Gene Therapy
CCapsida Biotherapeutics, Inc.
Phase 3
Elelyso
SShaare Zedek Medical Center
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AVR-RD-02. EMBL-EBI & Wellcome Sanger Institute.
- [4]